ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen)
- PMID: 22860166
- PMCID: PMC3369760
- DOI: 10.1021/cn200061g
ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen)
Abstract
STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209_ASD_P2b Trial_Initiation%206%2021%202011%20Final.pdf).
Keywords: GABA; STX209; autism spectrum disorder (ASD).
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
